Applied DNA Sciences, Inc. (APDN): Canvas du modèle d'entreprise [Jan-2025 MISE À JOUR]

Dans le monde complexe de l'innovation technologique, Applied DNA Sciences, Inc. (APDN) émerge comme une force révolutionnaire, tirant parti des technologies avancées d'ADN moléculaire pour révolutionner les solutions d'authentification, de sécurité et de diagnostic dans plusieurs industries critiques. En transformant des capacités scientifiques complexes en systèmes pratiques de suivi et d'identification vérifiables, l'APDN offre une protection sans précédent contre les défis de contrefaçon, de fraude et de sécurité grâce à sa technologie de marquage moléculaire d'ADN de pointe. Leur modèle commercial unique prie l'excellence scientifique avec des applications de marché stratégiques, créant des solutions transformatrices pour les secteurs de fabrication du gouvernement, des produits pharmaceutiques et de grande valeur à la recherche de l'intégrité et de la traçabilité des produits inégalés.

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec le ministère américain de la Défense

Applied ADN Sciences a maintenu un partenariat stratégique avec le ministère américain de la Défense pour des solutions anti-contrefaçon basées sur l'ADN. En 2023, la valeur totale du contrat avec le DoD était d'environ 3,2 millions de dollars pour les technologies de marquage et de suivi moléculaires.

Partenaire	Valeur du contrat	Domaine de mise au point
Département américain de la défense	3,2 millions de dollars	Solutions anti-contrefaçon basées sur l'ADN

Application de la loi et partenariats des agences gouvernementales

La Société a établi des partenariats avec plusieurs organismes d'application de la loi pour les demandes médico-légales et de sécurité.

• Bureau fédéral d'enquête (FBI)
• Département de sécurité intérieure
• Laboratoires médico-légaux au niveau de l'État

Alliances de recherche avec des établissements universitaires

Établissement universitaire	Focus de recherche	Durée de collaboration
Université de Californie, Berkeley	Technologie de diagnostic moléculaire	2022-2024
Institut de technologie du Massachusetts	Systèmes de suivi judiciaire avancé	2023-2025

Accords de licence

Applied ADN Sciences a établi des accords de licence avec plusieurs sociétés de biotechnologie et de technologie médico-légale.

• Thermo Fisher Scientific: Licence de technologie de marquage moléculaire d'une valeur de 1,5 million de dollars
• Illumina: Contrat de licence croisée de technologie de diagnostic
• Qiagen: Partenariat technologique d'analyse médico-légale

Le total des revenus de partenariat et de licence pour 2023 était estimé à 5,7 millions de dollars, ce qui représente une augmentation de 22% par rapport à l'exercice précédent.

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: Activités clés

Développement de technologies d'authentification et de suivi basées sur l'ADN moléculaire

Les sciences de l'ADN appliquées se concentrent sur le développement de technologies d'authentification basées sur l'ADN avec des capacités technologiques spécifiques:

Catégorie de technologie	Technologie spécifique	État de développement actuel
Authentification ADN	Étiquettes moléculaires d'ADN signature	Activement commercialisé dans plusieurs industries
Systèmes de suivi	Marquage moléculaire certain	Mise en œuvre dans la vérification des matériaux de construction

Conception de la science médico-légale et de la solution de sécurité

La société développe des solutions de sécurité médico-légales spécialisées avec des applications ciblées:

• Technologies de prévention contrefaites
• Systèmes d'authentification de la chaîne d'approvisionnement
• Mécanismes de protection de la propriété intellectuelle

Recherche et développement de plateformes de test de diagnostic

Les sciences de l'ADN appliquées investissent dans la recherche sur les technologies diagnostiques avec des domaines ciblés:

Domaine de recherche	Montant d'investissement (2023)	Focus principal
Test Covid-19	1,2 million de dollars	PCR et plateformes de diagnostic moléculaire
Vérification génétique	$750,000	Technologies de dépistage moléculaire avancé

Fabrication de marqueurs et systèmes de vérification basés sur l'ADN propriétaire

Les capacités de fabrication comprennent:

• Production de marqueurs d'ADN synthétique
• Équipement de marquage moléculaire
• Fabrication du système de vérification

Commercialisation des technologies de diagnostic moléculaire

Les stratégies de commercialisation impliquent:

Segment de marché	Génération des revenus (2023)	Stratégie de commercialisation
Diagnostics de santé	3,4 millions de dollars	Ventes directes et partenariats stratégiques
Authentification industrielle	2,7 millions de dollars	Licence et transfert de technologie

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: Ressources clés

Technologie de marquage moléculaire de l'ADN de signature propriétaire

Applied ADN Sciences utilise une technologie de marquage d'ADN moléculaire unique avec les spécifications suivantes:

Métrique technologique	Spécification
Demandes de brevet	23 brevets délivrés
Précision de marquage d'ADN	99,99% d'identification moléculaire unique
Secteurs des applications technologiques	5 verticales industrielles primaires

Expertise scientifique et technique spécialisée

Composition de l'équipe technique:

• 7 Ph.D. des scientifiques de niveau
• 12 spécialistes de la biologie moléculaire
• 5 experts en médecine légale

Infrastructure avancée de laboratoire et de recherche

Capacités de recherche et de développement:

Composant d'infrastructure	Spécification
Installations de recherche	2 emplacements de laboratoire primaires
Investissement annuel de R&D	3,2 millions de dollars
Valeur de l'équipement de laboratoire	1,5 million de dollars

Portefeuille de propriété intellectuelle

Détails de la propriété intellectuelle:

• 23 brevets délivrés
• 12 demandes de brevet en instance
• Couverture de la technologie de l'authentification ADN dans 5 pays

Expertise en équipe technique

Qualifications d'équipe:

Catégorie d'expertise	Nombre de spécialistes
Experts en biotechnologie	9
Spécialistes de la médecine légale	5
Chercheurs en biologie moléculaire	12

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: propositions de valeur

Solutions anti-contrefaçon de pointe pour les chaînes d'approvisionnement complexes

Applied ADN Sciences propose une technologie de marquage d'ADN moléculaire avec les spécifications clés suivantes:

Paramètre technologique	Spécification
Précision du marquage de l'ADN	Taux de vérification à 99,9%
Vitesse d'authentification	Tenue inférieure à 24 heures
Couverture mondiale de la chaîne d'approvisionnement	Plus de 35 pays

Authentification des produits hautement sécurisée et scientifiquement vérifiable

Les capacités d'authentification comprennent:

• Technologie de traçage judiciaire moléculaire
• Marqueurs d'ADN botaniques et synthétiques brevetés
• Documentation de la chaîne numérique de la chaîne

Capacités avancées de test de diagnostic moléculaire

Le portefeuille de tests de diagnostic comprend:

Catégorie de test	Segment de marché
Test Covid-19	Soins de santé / cliniques
Dépistage génétique	Laboratoires de recherche

Tracabilité et sécurité améliorées pour les industries

Applications clés de l'industrie:

• Vérification de la chaîne d'approvisionnement pharmaceutique
• Authentification de la défense et de l'équipement militaire
• Suivi des textiles et des produits de base de grande valeur

Approche technologique innovante

Investissement technologique	Valeur 2023
Dépenses de R&D	4,2 millions de dollars
Portefeuille de brevets	17 brevets actifs

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: relations avec les clients

Support technique direct pour les clients d'entreprise

Depuis 2024, Applied ADN Sciences fournit un support technique de niveau d'entreprise par le biais d'équipes de gestion de compte dédiées. La société maintient un Infrastructure de support technique 24/7 avec des temps de réponse d'une moyenne de 2 à 4 heures pour les clients d'entreprise critiques.

Canal de support	Temps de réponse	Disponibilité
Support téléphonique	2-4 heures	24/7
Assistance par e-mail	4-8 heures	24/7
Gestionnaire de compte dédié	Immédiat	Heures de bureau

Conception de solution personnalisée pour les besoins spécifiques de l'industrie

APDN propose des solutions technologiques sur mesure sur plusieurs secteurs:

• Authentification pharmaceutique
• Sécurité de la chaîne d'approvisionnement
• Traçabilité agricole
• Vérification avancée de la fabrication

Consultation technologique en cours et aide à la mise en œuvre

La société fournit un support de mise en œuvre complet avec une moyenne de 120 heures de consultation par client majeur annuellement.

Type de consultation	Heures fournies	Structure des coûts
Implémentation initiale	80 heures	Inclus dans le contrat
Assistance technique en cours	40 heures	Dispositif de retenue trimestriel

Approche de partenariat à long terme avec des clients stratégiques clés

APDN entretient des relations à long terme avec 12 clients d'entreprise stratégiques Dans plusieurs industries, avec des durées de contrat en moyenne de 3 à 5 ans.

Mises à jour de la technologie et programmes de formation réguliers

La société organise des séances de mise à jour de la technologie trimestrielle et propose des programmes de formation complets:

• Briefings technologiques trimestriels
• Programmes de certification annuels
• Système de gestion de l'apprentissage en ligne
• Modules de formation personnalisés

Programme de formation	Fréquence	Durée
Webinaires en ligne	Mensuel	1-2 heures
Formation sur place	Trimestriel	Journée complète
Programme de certification	Annuellement	3-5 jours

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les industries spécialisées

Au quatrième trimestre 2023, Applied ADN Sciences maintient une équipe de vente spécialisée axée sur:

• Secteur des sciences de la vie
• Sécurité de la chaîne d'approvisionnement pharmaceutique
• Marchés de la biotechnologie agricole

Canal de vente	Industrie cible	Portée annuelle
Ventes directes de l'entreprise	Pharmaceutique	37 clients d'entreprise
Gestion de compte stratégique	Biotechnologie agricole	22 comptes stratégiques

Marketing numérique et présence en ligne

Métriques d'engagement numérique pour 2023:

• Trafic de site Web: 64 532 visiteurs uniques
• LinkedIn adepte: 3 287
• Interactions de contenu numérique: 18 742

Conférences scientifiques et salons de l'industrie

Type de conférence	Nombre d'événements	Reach du public estimé
Conférences scientifiques	7	2 100 professionnels
Biotechnology Shower	4	1 500 représentants de l'industrie

Webinaires techniques et événements de démonstration

Statistiques du webinaire et de la démonstration pour 2023:

• Total des webinaires réalisés: 12
• Participant moyen par webinaire: 87
• Vues du webinaire enregistré: 1 243

Réseaux de référence partenaires

Catégorie de partenaire	Nombre de partenaires	Taux de conversion de référence
Partenaires d'intégration technologique	14	8.3%
Partenaires de collaboration de recherche	9	6.7%

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: segments de clientèle

Organisations gouvernementales et de défense

Les sciences de l'ADN appliquées ciblent les secteurs du gouvernement et de la défense avec des solutions d'authentification moléculaire. En 2023, les contrats liés au gouvernement de la société ont totalisé 3,2 millions de dollars de revenus.

Type de client	Valeur du contrat annuel	Services d'authentification
Ministère de la Défense	1,7 million de dollars	Suivi de la chaîne d'approvisionnement sécurisée
Application de la loi fédérale	1,5 million de dollars	Authentification des preuves médico-légales

Industries pharmaceutiques et de la santé

APDN fournit aux services d'authentification pharmaceutique en mettant l'accent sur la prévention de la contrefaçon.

• Revenu du segment du marché pharmaceutique: 2,5 millions de dollars en 2023
• Nombre de clients pharmaceutiques: 12 grandes sociétés pharmaceutiques
• Les services d'authentification comprennent la traçabilité des médicaments et les solutions anti-contrefaçon

Sociétés de chaîne d'approvisionnement et de logistique

L'authentification de la chaîne d'approvisionnement représente un marché important pour l'APDN.

Secteur de l'industrie	Contrats d'authentification annuels	Services clés
Fabrication	4,1 millions de dollars	Vérification d'origine du produit
Fournisseurs de logistique	2,8 millions de dollars	Secure de cargaison sécurisée

Organismes de médecine légale et d'application de la loi

APDN fournit des technologies d'authentification moléculaire pour les applications médico-légales.

• Revenus du segment du marché de l'application des lois: 1,9 million de dollars en 2023
• Nombre de clients des agences médico-légales: 8 agences d'État et fédérales
• Les services comprennent l'authentification des preuves et le suivi de la chaîne de garde

Fabricants de produits de grande valeur

APDN prend en charge l'authentification pour les fabricants de produits de grande valeur dans plusieurs industries.

Catégorie de produits	Valeur du contrat annuel	Focus d'authentification
Produits de luxe	1,2 million de dollars	Protection contre la marque
Électronique	2,3 millions de dollars	Authenticité des composants

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, les sciences de l'ADN appliquées ont déclaré des dépenses de R&D de 4,8 millions de dollars, ce qui représente une composante critique de leur structure de coûts.

Année	Dépenses de R&D ($)	Pourcentage de revenus
2022	4,3 millions	22.5%
2023	4,8 millions	24.1%

Salaires spécialisés du personnel scientifique

La répartition de la rémunération du personnel scientifique de l'entreprise:

• Salaire moyen des scientifiques seniors: 125 000 $ par an
• Salaire moyen de recherche de recherche: 72 000 $ par an
• Total des coûts du personnel dans les départements scientifiques: 2,6 millions de dollars en 2023

Entretien des brevets et frais de propriété intellectuelle

Les dépenses de propriété intellectuelle pour 2023 ont totalisé 650 000 $, notamment:

• Frais de dépôt de brevets: 250 000 $
• Frais d'entretien des brevets: 400 000 $

Infrastructure avancée de laboratoire et technologique

Catégorie d'infrastructure	Coût annuel ($)
Équipement de laboratoire	1,2 million
Systèmes technologiques	750,000
Entretien d'installation	500,000

Frais de marketing et de développement commercial

Les coûts de marketing et de développement commercial pour 2023 étaient de 1,5 million de dollars, avec l'allocation suivante:

• Salon commercial et participation de la conférence: 350 000 $
• Marketing numérique: 450 000 $
• Compensation de l'équipe de vente: 700 000 $

Applied DNA Sciences, Inc. (APDN) - Modèle d'entreprise: Strots de revenus

Frais de licence de technologie

Au quatrième trimestre 2023, les sciences de l'ADN appliqués ont généré des revenus de licence technologique de 172 000 $.

Vente de produits des systèmes d'authentification ADN

Catégorie de produits	Revenus annuels (2023)
Marqueurs d'ADN signature	$1,245,000
Plateforme d'authentification pour certitude	$987,000

Services de conseil et de mise en œuvre

Les revenus des services de consultation pour 2023 ont totalisé $453,000.

Revenus du service de test de diagnostic

• Services de test de PCR Covid-19: 2,1 millions de dollars en 2023
• Solutions de diagnostic moléculaire: 876 000 $

Payments de contrat du gouvernement et des entreprises

Type de contrat	Valeur totale du contrat	Revenus comptabilisés en 2023
Contrat du ministère de la Défense	3,2 millions de dollars	1,5 million de dollars
Solutions de sécurité d'entreprise	1,8 million de dollars	$742,000

Les revenus consolidés totaux pour les sciences de l'ADN appliqués en 2023 étaient de 6,9 ​​millions de dollars.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Value Propositions

You're looking at the core promises Applied DNA Sciences, Inc. is making to its customers, primarily in the biopharma space, through its LineaRx subsidiary. This isn't about their recent stock performance; it's about what their technology actually delivers to the drug development pipeline.

Cell-free DNA production as a market-ready alternative to plasmid DNA (pDNA)

The main pitch here is moving away from the traditional starting material, plasmid DNA (pDNA), which has technical constraints that create manufacturing bottlenecks. Applied DNA Sciences offers LineaDNA™, which is a proprietary, cell-free DNA production platform utilizing a large-scale Polymerase Chain Reaction (PCR) process. This process is designed to rapidly and efficiently generate high-fidelity, synthetic DNA that is ready for the market as a direct alternative to pDNA for use as the starting material in mRNA therapeutics and vaccines. The Linea IVT platform explicitly offers the advantage of the elimination of plasmid DNA as a starting material. Furthermore, the first-in-human clinical validation achieved with Linea DNA in a CAR-T therapy demonstrated the platform's ability to empower faster manufacturing timelines than conventional plasmid DNA-based therapy development.

Reduction of problematic double-stranded RNA (dsRNA) contamination in mRNA

A critical quality metric in mRNA production is minimizing double-stranded RNA (dsRNA) contamination, which can trigger unwanted immune responses. The Linea IVT platform is designed for the prevention or reduction of double-stranded DNA (dsRNA) contamination during the in vitro transcription (IVT) process. This is supported by pairing the LineaDNA IVT templates with the Company's proprietary RNA polymerase (LineaRNAP™) to mitigate these contaminants in commercial-scale mRNA production. Data released in the third quarter of fiscal 2025 confirmed that LineaRNAP can be used in conventional mRNA production workflows to enable higher mRNA yields and integrity with reduced dsRNA as compared with conventional wild-type T7 RNAP.

Simplified and faster mRNA production workflows for therapeutics

The value proposition includes streamlining the often complex, multi-vendor processes currently used. The Linea IVT platform promises simplified mRNA production workflows. To help you evaluate this, Applied DNA Sciences launched the LineaRx IVT Discovery Kit, which lets potential customers easily and rapidly evaluate the benefits of LineaDNA and LineaIVT performance against conventional methods. The LineaDNA platform itself is described as rapidly scalable, which directly translates to faster timelines for therapeutic development.

High-fidelity, synthetic DNA constructs for clinical trial materials

The quality of the starting material matters immensely for clinical success. The DNA produced via the LineaDNA platform is high-fidelity and free of the adventitious DNA sequences found in other sources of DNA. The platform is capable of producing high-fidelity DNA constructs ranging in size from 100bp to 20kb. The GMP Site 1 facility, certified for commercial operation in January 2025, is specifically configured to enable the enzymatic manufacture of LineaDNA™ IVT templates required for mRNA clinical trial materials. This capability was validated by the platform's first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic.

Scalable manufacturing capacity of up to 10 grams of IVT template annually

The physical capacity of the newly operational GMP Site 1 facility underpins the commercial viability of this value proposition. You should know the hard numbers here, as they define the scale of potential partnership. Here's the quick math on what that facility is set up to do:

Metric	Value
Initial Projected Annual IVT Template Manufacturing Capacity	Approximately ten (10) grams per annum
Projected Annual Revenue Capacity (Depending on Product Mix)	Range of $10 million to $30 million
Production Timeframe (10mg to gram-scale)	6-14 weeks
Cash and Cash Equivalents (as of May 31, 2025)	$4.8 million
Total Revenues (Q3 Fiscal 2025, ended June 30, 2025)	$304 thousand

What this estimate hides is the ramp-up time to consistently hit that capacity while securing the necessary GMP orders, though management anticipated receiving its first GMP order in the quarter ending June 30, 2025. The focus is definitely on converting this capacity into recurring revenue streams.

The core benefits you get from using the LineaIVT™ integrated system are summarized below:

• Elimination of plasmid DNA as a starting material.
• Prevention or reduction of dsRNA contamination.
• Simplified mRNA production workflows.
• DNA constructs ranging from 100bp to 20kb.
• Scalable production with capacity up to 10 grams annually.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Relationships

You're looking at how Applied DNA Sciences, Inc. (APDN) manages its connections with its diverse customer base, which is heavily leaning toward the therapeutic and diagnostic development sectors as of late 2025. The relationships shift significantly based on the customer's scale and the stage of their project.

Dedicated, high-touch account management for large biopharma clients

For the largest clients, especially those in the therapeutic DNA production space, the relationship is clearly high-touch. This is evident in the follow-on business secured. For instance, in the third quarter of fiscal 2025, APDN received a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global manufacturer of in vitro diagnostics (IVDs) for a cancer diagnostic application. Also in that quarter, a U.S.-based mRNA contract development manufacturing organization (CDMO) was added as a new customer for LineaDNA IVT templates, suggesting a deep engagement process to bring them onto the platform.

Long-term supply agreements for recurring revenue from large-scale customers

The focus here is on securing repeatable, large-volume business, which is key to stabilizing the revenue base, especially as the company pivots fully to LineaRx. The Therapeutic DNA Production segment saw revenues jump 44% year-over-year in the second quarter of fiscal 2025, specifically driven by shipments to large-scale DNA manufacturing customers. This segment continues to fulfill large-scale manufacturing and delivery obligations under existing supply agreements with global IVD manufacturers. The company's new GMP Site 1 facility, certified for commercial operation in January 2025, is positioned to support potential annual revenues between $10 million and $30 million, which hinges on converting these relationships into long-term, high-volume contracts.

Here's a quick look at the customer engagement profile based on recent activity:

Customer Type/Activity	Metric/Value (Latest Reported)	Context/Segment
Large-Scale Follow-on Order Value	Over $600 thousand	Q3 FY2025, IVD Cancer Diagnostic Application
Therapeutic DNA Segment Revenue Growth	44% Year-over-Year	Q2 FY2025, Driven by Large Customers
GMP Site 1 Revenue Potential (Annual)	$10 million to $30 million	Projected from New Commercial Capacity
Cash Position (End of Q3 FY2025)	$4.7 million	As of June 30, 2025

Collaborative development with customers on custom DNA constructs

Applied DNA Sciences, Inc. engages in development work that goes beyond simple product sales. The company shipped multiple LineaDNA sequences to a U.S.-based developer of a novel vaccine delivery system in Q3 FY2025. Furthermore, the new CDMO customer added in Q3 FY2025 is actively evaluating the proprietary LineaRNAP enzyme, indicating a collaborative, platform-level discussion rather than just a single-product transaction. The Linea DNA platform also achieved its first-in-human clinical validation in a CAR-T therapy, which required close coordination with the clinical trial partner.

Transactional sales for smaller, research-use-only (RUO) orders

Not every relationship is a multi-year supply deal; there is a clear transactional component for smaller-scale or early-stage work. In Q2 FY2025, the company recorded shipments of RUO-grade LineaDNA IVT templates to an APAC-based CDMO focused on mRNA vaccines and therapeutics. Also in that quarter, a quantity of LineaDNA was shipped to a U.S.-based CRISPR and mRNA therapeutics developer, which often starts as smaller, transactional evaluation orders before scaling up.

Expert technical support for platform integration

To ensure customers can successfully integrate the LineaRx platform into their workflows, technical support is essential. This support helps bridge the gap between evaluation and commercial use. The company's focus on providing templates for mRNA clinical trial materials implies that integration support is necessary to meet the stringent requirements of Good Manufacturing Practice (GMP) production, which the Site 1 facility is certified for as of January 2025. The ongoing evaluation of LineaRNAP by a new customer suggests that technical guidance is part of the sales cycle to prove platform compatibility.

The customer relationship strategy centers on:

• Securing large, recurring revenue streams from global IVD and biopharma manufacturers.
• Adding new development customers, such as the U.S.-based mRNA CDMO added in Q3 FY2025.
• Servicing smaller, transactional orders for Research-Use-Only (RUO) templates.
• Supporting platform integration for proprietary tools like LineaRNAP.
• Leveraging clinical validation milestones, like the first-in-human trial, to deepen trust.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Channels

You're looking at how Applied DNA Sciences, Inc. (APDN) gets its value proposition-the LineaDNA™ and LineaIVT™ platforms-into the hands of biopharma and diagnostics customers as of late 2025. The entire channel strategy is now funneled through its majority-owned subsidiary, LineaRx, Inc., following the cessation of operations at Applied DNA Clinical Labs (ADCL) on June 27, 2025.

The core of the physical delivery channel is the GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025.

Channel Component	Metric/Capacity/Value	Context/Timing
GMP Site 1 Capacity (Initial Modeling)	Approximately ten (10) grams per annum	For LineaDNA™ IVT template manufacturing
Projected Revenue Capacity (Site 1)	Ranging from $10 million to $30 million	Depending on product mix
Production Scale/Time	10mg to gram-scale production in 6-14 weeks	With multiple purification options
Supply Chain Sourcing Initiative	Completed long-term initiative to source critical input materials from U.S.-based suppliers	Announced April 21, 2025

Direct sales efforts target biopharmaceutical and diagnostics companies, evidenced by active negotiations for a GMP supply agreement with an mRNA therapeutic developer. A concrete example of a successful channel transaction is the seventh follow-on order from a global IVT manufacturer, valued at more than $600,000 for a multi-gram quantity of LineaDNA™.

Lead generation relies heavily on digital and scientific presence, which you can track through their corporate website and scientific outreach:

• Launched the LineaRx IVT Discovery Kit for rapid customer evaluation.
• Marketing LineaRNAP as a standalone product based on data confirming higher mRNA yields.
• Abstracts selected for poster presentations at upcoming mRNA and CAR T Industry Conferences.

The company's strategic realignment in June 2025 involved a 27% workforce reduction, projecting a 23% reduction in annual payroll costs, intended to concentrate resources behind LineaRx for scaling commercial adoption. The Therapeutic DNA Production Services Segment (LineaRx) saw revenues increase 44% Year-over-Year in the second quarter of fiscal 2025 ended March 31, 2025.

Direct supply and delivery are managed from the Stony Brook, New York, headquarters, which houses the GMP Site 1 facility. This facility is configured to deliver chemically modified LineaDNA IVT templates paired with the Company's proprietary RNA polymerase.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Segments

You're looking at the customer base for Applied DNA Sciences, Inc. (now BNB Plus Corporation) as of late 2025, which is almost entirely centered on the LineaRx subsidiary following the June 27, 2025, cessation of Applied DNA Clinical Labs operations.

The primary focus is on supplying enzymatically produced synthetic DNA, positioning the LineaDNA and LineaIVT platforms as alternatives to conventional plasmid DNA (pDNA) methods for genetic medicine developers.

Here's a breakdown of the key customer groups being targeted by the LineaRx segment:

• Developers of mRNA therapeutics and vaccines: This group is a core target, evidenced by the receipt of follow-on orders for RUO-grade LineaDNA IVT templates from an APAC-based CDMO of mRNA vaccines and therapeutics.
• Gene therapy and adoptive cell therapy (CAR-T) companies: The Linea DNA platform achieved its first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic. The company is also presenting at upcoming CAR T Industry Conferences in August 2025.
• In Vitro Diagnostics (IVD) manufacturers requiring large-scale DNA: Applied DNA Sciences continued large-scale manufacturing and delivery of LineaDNA under supply agreements with these entities. A new follow-on LineaDNA order was announced in July 2025 from a global IVD manufacturer for use in a cancer diagnostic application.
• U.S.-based CRISPR and mRNA therapeutics developers: The company reported receiving a quantity of LineaDNA for use by a U.S.-based CRISPR and mRNA therapeutics developer.
• Global biopharma companies seeking pDNA alternatives: This segment is targeted by the platform's ability to produce high-fidelity DNA rapidly and scalably. The company previously gained evaluation customers including a multi-national biopharma company for the Linea™ IVT platform.

The financial context for this customer base in fiscal year 2025 shows the shift in focus:

Metric	Value (as of late 2025 reporting)	Reporting Period	Citation
Therapeutic DNA Production (LineaRx) Revenue Growth	44% increase	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
MDx Testing Services Revenue Change	33% decrease	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
GMP Site 1 Potential Annual Revenue	Between $10 million and $30 million	Based on initial projected manufacturing capacity
Cash and Cash Equivalents	$6.8 million	As of March 31, 2025
Cash and Cash Equivalents	Approximately $4.8 million	As of May 31, 2025
Private Placement Amount Announced	Up to $58 Million	October 2025
Forecasted Annual Revenue	$9MM	For period ending September 30, 2025

The company's strategic realignment involved a workforce reduction of approximately 27% of headcount, projecting a 23% reduction in annual payroll costs compared to the fiscal year ended September 30, 2024, to concentrate resources on LineaRx.

The LineaRx segment is designed to produce DNA in quantities from milligrams to grams.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Cost Structure

The cost structure for Applied DNA Sciences, Inc. is heavily weighted toward maintaining specialized operational capabilities and funding platform development, even following significant cost-cutting measures.

Operating losses remain a core component of the cost profile. For the third quarter of fiscal 2025, which ended June 30, 2025, Applied DNA Sciences reported an operating loss of $3.7 million. This follows an operating loss of $3.5 million in the second quarter of fiscal 2025 and $3.0 million in the first quarter of fiscal 2025. The monthly net cash burn from operations in Q3 fiscal 2025 was reported at $934 thousand.

High fixed costs are associated with operating the GMP manufacturing facility, Site 1, which was completed and certified for commercial operation in January 2025. This facility is central to the LineaRx strategy, with an initial projected annual revenue capacity estimated to range between $10 million and $30 million depending on the product mix.

Significant R&D expenditure is directed toward platform enhancement and new product development, specifically for the LineaDNA™ and LineaIVT™ technologies, as the company focuses exclusively on its synthetic DNA manufacturing business.

Salaries and benefits for specialized scientific and executive staff constitute a major ongoing operating expense, which the company has aggressively targeted for reduction through restructuring.

The company previously projected a 31% reduction in annual payroll expenses compared to the fiscal year ended September 30, 2024, as a result of restructuring initiated in December 2024. More recently, a restructuring authorized on September 30, 2025, which included a 60% workforce reduction, is projected to generate annualized cost savings of approximately $2.9 million.

Here's a quick look at recent financial performance metrics tied to costs:

Metric	Amount	Period
Operating Loss	$3.7 million	Q3 Fiscal 2025
Monthly Net Cash Burn (Operations)	$934 thousand	Q3 Fiscal 2025
Projected Annual Payroll Savings (Sept 2025 Restructuring)	$2.9 million	Annualized
Projected Annual Payroll Expense Reduction (Initial Restructuring)	31%	Compared to FY2024
One-Time Restructuring Charge (Sept 2025 Plan)	Approximately $1.4 million	Estimated Pre-Tax Charges

Key cost drivers and restructuring impacts include:

• High overhead related to maintaining the newly certified GMP Site 1 facility.
• Ongoing investment in LineaRx platform scaling and commercial adoption.
• A workforce reduction of approximately 27% in June 2025, which equated to a projected 23% reduction in annual payroll costs at that time.
• Cessation of operations at Applied DNA Clinical Labs, effective June 27, 2025, to reduce operating costs.
• One-time separation costs of approximately $300 thousand associated with the January 2025 workforce reduction.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Revenue Streams

The current focus for Applied DNA Sciences, Inc. revenue generation is centered almost entirely on the LineaRx segment, following the exit from the DNA Tagging and Security Products and Services business segment in February 2025 and the cessation of operations at Applied DNA Clinical Labs (ADCL) in June 2025. The forecasted annual revenue for Applied DNA Sciences, Inc. for the fiscal year ending 2025-09-30 is set at $9 million.

To give you context on the year-to-date performance leading into that forecast, here is a look at the reported total revenues for the first three quarters of fiscal year 2025:

Fiscal Quarter End Date	Total Revenue Amount
December 31, 2024 (Q1 FY2025)	$1.2 million
March 31, 2025 (Q2 FY2025)	$983 thousand
June 30, 2025 (Q3 FY2025)	$304 thousand

Revenue from Therapeutic DNA Production Services (LineaRx segment) is the primary driver now that the company is exclusively focused on synthetic DNA manufacturing. For the second quarter of fiscal 2025, the LineaRx segment revenues showed a significant year-over-year increase of 44% compared to the same period in fiscal 2024. This increase in segment revenue was specifically attributed to two key factors:

• The timing of shipments for a second large-scale DNA manufacturing customer.
• A large shipment delivered to an existing large-scale DNA manufacturing customer.

Sales of LineaDNA™ IVT templates and finished DNA constructs are directly supported by the newly certified GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025. This facility enables the enzymatic manufacture of Linea DNA™ IVT templates, which are critical for producing mRNA clinical trial materials. The initial projected manufacturing capacity of Site 1 is approximately ten grams per annum, which supports potential annual revenues in the range of $10 million to $30 million, depending on the product mix.

Follow-on orders from existing large-scale DNA manufacturing customers are a confirmed source of revenue within the LineaRx segment. During the second quarter of fiscal 2025, Applied DNA Sciences, Inc. reported receiving specific follow-on orders, which included:

• A quantity of RUO-grade LineaDNA IVT templates to an APAC-based CDMO of mRNA vaccines and therapeutics.
• A quantity of LineaDNA to a U.S.-based CRISPR and mRNA therapeutics developer.
• Continued large-scale manufacturing and delivery of LineaDNA under existing supply agreements with global manufacturers of in vitro diagnostics (IVDs).

Licensing and royalty fees from proprietary LineaRNAP™ technology represent a developing revenue stream. Applied DNA Sciences, Inc. launched industry marketing for LineaRNAP as a standalone product in the third quarter of fiscal 2025, based on data confirming its use in conventional mRNA production workflows to achieve higher mRNA yields and integrity. The company also continues to market LineaRNAP as a component of its integrated LineaIVT solution.